Fig. 6

A schematic representation illustrating the anti-cancer activity of TMEM52B ECD-derived peptides. TMEM52B ECD-derived peptides stabilized intact E-cadherin at cell–cell junctions, leading to reduced β-catenin transcriptional activity. They also inhibited generation of soluble E-cadherin and the activation of EGFR by interfering with the interaction between soluble E-cadherin and EGFR. These activities may reduce tumor growth and early metastasis. The nucleus was not distinguished. The dashed arrow indicates translocation